Tokyo Tape
Sign in
← Terumo

Quarterly report · Q3

4543.TEDINET S100SSIE
Period2023-04-01 → 2023-12-31
Filed2024-02-09
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥683.0bn2023-04-01 → 2023-12-31Cons.Revenue IFRS
Revenue¥239.1bn2023-10-01 → 2023-12-31dCons.Revenue IFRS
Revenue¥820.2bn2022-04-01 → 2023-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥618.0bn2022-04-01 → 2022-12-31Cons.Revenue IFRS
Revenue¥214.7bn2022-10-01 → 2022-12-31dCons.Revenue IFRS
Operating income¥105.5bn2023-04-01 → 2023-12-31Cons.Operating profit loss IFRS
Operating income¥39.0bn2023-10-01 → 2023-12-31dCons.Operating profit loss IFRS
Operating income¥93.5bn2022-04-01 → 2022-12-31Cons.Operating profit loss IFRS
Operating income¥37.5bn2022-10-01 → 2022-12-31dCons.Operating profit loss IFRS
Profit before tax¥105.7bn2023-04-01 → 2023-12-31Cons.Profit loss before tax IFRS
Profit before tax¥39.3bn2023-10-01 → 2023-12-31dCons.Profit loss before tax IFRS
Profit before tax¥116.1bn2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥92.1bn2022-04-01 → 2022-12-31Cons.Profit loss before tax IFRS
Profit before tax¥37.5bn2022-10-01 → 2022-12-31dCons.Profit loss before tax IFRS
Net income (owners)¥79.9bn2023-04-01 → 2023-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥29.8bn2023-10-01 → 2023-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥89.3bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥70.2bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥29.9bn2022-10-01 → 2022-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income¥79.9bn2023-04-01 → 2023-12-31Cons.Profit loss IFRS
Net income¥29.8bn2023-10-01 → 2023-12-31dCons.Profit loss IFRS
Net income¥70.2bn2022-04-01 → 2022-12-31Cons.Profit loss IFRS
Net income¥29.9bn2022-10-01 → 2022-12-31dCons.Profit loss IFRS
Total assets¥1.69Tat 2023-12-31Cons.Assets IFRS
Total assets¥1.60Tat 2023-03-31Cons.Assets IFRS
Total assets¥1.54Tat 2022-12-31Cons.Total assets IFRS (5-year summary)
Total liabilities¥475.7bnat 2023-12-31Cons.Liabilities IFRS
Total liabilities¥491.2bnat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥1.22Tat 2023-12-31Cons.Equity IFRS
Net assets / equity¥1.11Tat 2023-03-31Cons.Equity IFRS
Net assets / equity¥1.07Tat 2022-12-31Cons.Equity IFRS
Net assets / equity¥1.01Tat 2022-03-31dCons.Equity IFRS
Equity (owners)¥1.22Tat 2023-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.11Tat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.07Tat 2022-12-31Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥163.6bnat 2023-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥187.3bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥162.4bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥205.3bnat 2022-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥91.2bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥117.5bn2022-04-01 → 2023-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥74.9bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥53.1bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥59.1bn2022-04-01 → 2023-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥41.9bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥68.7bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥86.6bn2022-04-01 → 2023-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥84.5bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥107.332023-04-01 → 2023-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥40.062023-10-01 → 2023-12-31dCons.Basic earnings loss per share IFRS
EPS (basic)¥1192022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥93.252022-04-01 → 2022-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥39.972022-10-01 → 2022-12-31dCons.Basic earnings loss per share IFRS
EPS (diluted)¥107.292023-04-01 → 2023-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥40.052023-10-01 → 2023-12-31dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥118.952022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥93.212022-04-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥39.962022-10-01 → 2022-12-31dCons.Diluted earnings loss per share IFRS
Equity ratio71.9%at 2023-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio69.3%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio69.6%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 20
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue external2023-04-01 → 2023-12-31¥172m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-12-31−¥2.1bn
jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segmentrevenue external2023-04-01 → 2023-12-31¥127.8bn
jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segmentsegment profit2023-04-01 → 2023-12-31¥13.9bn
jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segmentrevenue external2023-04-01 → 2023-12-31¥407.7bn
jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segmentsegment profit2023-04-01 → 2023-12-31¥92.0bn
jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segmentrevenue external2023-04-01 → 2023-12-31¥147.3bn
jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segmentsegment profit2023-04-01 → 2023-12-31¥16.0bn
—segment totalrevenue external2023-04-01 → 2023-12-31¥682.8bn
—segment totalsegment profit2023-04-01 → 2023-12-31¥121.9bn
Reconciling Itemsreconcilingrevenue external2022-04-01 → 2022-12-31¥186m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31¥479m
jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segmentrevenue external2022-04-01 → 2022-12-31¥113.4bn
jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segmentsegment profit2022-04-01 → 2022-12-31¥12.9bn
jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segmentrevenue external2022-04-01 → 2022-12-31¥358.9bn
jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segmentsegment profit2022-04-01 → 2022-12-31¥83.6bn
jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segmentrevenue external2022-04-01 → 2022-12-31¥145.5bn
jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segmentsegment profit2022-04-01 → 2022-12-31¥12.6bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥617.8bn
—segment totalsegment profit2022-04-01 → 2022-12-31¥109.1bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 653
ItemContextValueUnit
Profit loss IFRSCurrentYTDDuration_CapitalSurplusIFRSMember－JPY
Profit loss IFRSCurrentYTDDuration_TreasurySharesIFRSMember－JPY
Profit loss IFRSCurrentYTDDuration_RetainedEarningsIFRSMember79897000000JPY
Profit loss IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember－JPY
Profit loss IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember79897000000JPY
Profit loss IFRSCurrentYTDDuration79897000000JPY
Other comprehensive income IFRSCurrentYTDDuration_ShareCapitalIFRSMember－JPY
Other comprehensive income IFRSCurrentYTDDuration_CapitalSurplusIFRSMember－JPY
Other comprehensive income IFRSCurrentYTDDuration_TreasurySharesIFRSMember－JPY
Other comprehensive income IFRSCurrentYTDDuration_RetainedEarningsIFRSMember－JPY
Other comprehensive income IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember64764000000JPY
Other comprehensive income IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember64764000000JPY
Other comprehensive income IFRSCurrentYTDDuration64764000000JPY
Comprehensive income IFRSCurrentYTDDuration_ShareCapitalIFRSMember－JPY
Comprehensive income IFRSCurrentYTDDuration_CapitalSurplusIFRSMember－JPY
Comprehensive income IFRSCurrentYTDDuration_TreasurySharesIFRSMember－JPY
Comprehensive income IFRSCurrentYTDDuration_RetainedEarningsIFRSMember79897000000JPY
Comprehensive income IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember64764000000JPY
Comprehensive income IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember144662000000JPY
Comprehensive income IFRSCurrentYTDDuration144662000000JPY
Purchase of treasury shares ss IFRSCurrentYTDDuration_ShareCapitalIFRSMember－JPY
Purchase of treasury shares ss IFRSCurrentYTDDuration_CapitalSurplusIFRSMember-5000000JPY
Purchase of treasury shares ss IFRSCurrentYTDDuration_TreasurySharesIFRSMember-7942000000JPY
Purchase of treasury shares ss IFRSCurrentYTDDuration_RetainedEarningsIFRSMember－JPY
Purchase of treasury shares ss IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember－JPY
Purchase of treasury shares ss IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember-7947000000JPY
Purchase of treasury shares ss IFRSCurrentYTDDuration-7947000000JPY
Disposal of treasury shares ss IFRSCurrentYTDDuration_ShareCapitalIFRSMember－JPY
Disposal of treasury shares ss IFRSCurrentYTDDuration_CapitalSurplusIFRSMember-104000000JPY
Disposal of treasury shares ss IFRSCurrentYTDDuration_TreasurySharesIFRSMember185000000JPY
Disposal of treasury shares ss IFRSCurrentYTDDuration_RetainedEarningsIFRSMember－JPY
Disposal of treasury shares ss IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember-81000000JPY
Disposal of treasury shares ss IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember0JPY
Disposal of treasury shares ss IFRSCurrentYTDDuration0JPY
Dividends ss IFRSCurrentYTDDuration_ShareCapitalIFRSMember－JPY
Dividends ss IFRSCurrentYTDDuration_CapitalSurplusIFRSMember－JPY
Dividends ss IFRSCurrentYTDDuration_TreasurySharesIFRSMember－JPY
Dividends ss IFRSCurrentYTDDuration_RetainedEarningsIFRSMember-32020000000JPY
Dividends ss IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember－JPY
Dividends ss IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember-32020000000JPY
Dividends ss IFRSCurrentYTDDuration-32020000000JPY
Transfer from retained earnings to capital surplus IFRSCurrentYTDDuration_ShareCapitalIFRSMember－JPY
Transfer from retained earnings to capital surplus IFRSCurrentYTDDuration_CapitalSurplusIFRSMember72000000JPY
Transfer from retained earnings to capital surplus IFRSCurrentYTDDuration_TreasurySharesIFRSMember－JPY
Transfer from retained earnings to capital surplus IFRSCurrentYTDDuration_RetainedEarningsIFRSMember-72000000JPY
Transfer from retained earnings to capital surplus IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember－JPY
Transfer from retained earnings to capital surplus IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember－JPY
Transfer from retained earnings to capital surplus IFRSCurrentYTDDuration－JPY
Transfer from other components of equity to retained earnings ss IFRSCurrentYTDDuration_ShareCapitalIFRSMember－JPY
Transfer from other components of equity to retained earnings ss IFRSCurrentYTDDuration_CapitalSurplusIFRSMember－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-12-31pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-10-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-10-01/2023-12-31pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-12-31pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2022-10-01/2022-12-31pass
statement vs summary · revenueconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2023-10-01/2023-12-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass